Two pharmaceutical companies are listed in 2018 to create 50 "genius companies" in the future

[China Pharmaceutical network industry trends] recently, Time magazine released the top 50 "talent companies" that create the future in 2018 Two pharmaceutical companies were listed, one is MSD, the other is GW pharmaceutical The author of MSD understands that MSD is enjoying the achievements of its PD-1 inhibitor keytruda (pembrolizumab / pabolizumab) in various parts of the world, because the quarterly sales of the immunotherapy drug exceeds that of its competitor, opdivo (nivolumab / nafulizumab), the PD-1 inhibitor of Bristol Myers Squibb Keytruda generated $1.66 billion in revenue in the second quarter, an 86% year-on-year growth rate (calculated by CER), which pushed global sales to $10.5 billion, up 5.0% year-on-year, according to Mercer East Financial In addition to keytruda, the vaccine business is also one that mosadon cannot ignore From the perspective of vaccine product line, from the traditional children's vaccine (including smallpox, mumps, measles), to the new generation of HPV vaccine, rotavirus vaccine, etc., there are 12 vaccine products on sale in MSD, and some vaccines are under review, or in phase II and phase III clinical trials In addition, hepatitis C drugs are the power that mesardon can rely on It is reported that although the reduction of hepatitis C market has a great impact on all enterprises, the other advantage of MSD compared with other manufacturers is that it has established a solid Promotion Foundation in Japan and China with the sales of interferon and ribavirin for many years "We are optimistic about China's long-term growth opportunities," said one executive Frankly speaking, China's demand is much larger than we expected, and we are still trying to make sure we understand the demand there, because this is a huge opportunity There are so many people there, we have to understand how many products are needed to enter the country " GW pharmaceutical is a biopharmaceutical company Although it is not famous for MSD, its products are groundbreaking The author understands that GW pharmaceutical was founded in 1998, headquartered in Cambridge, UK, with 593 full-time employees It is a biopharmaceutical company specializing in the discovery, development and commercialization of cannabis prescription drugs It is a global company approved to launch sativex In 2016, GW pharmaceutical announced that its epilepsy, which uses hemp extract as the active ingredient, had good clinical performance in the treatment of phase III of Dravet syndrome The phase III clinical results will greatly improve the probability of FDA approval This significant positive also more than doubled its share price at that time Epidiolex is an oral, high-purity CBD extract liquid preparation CBD is a non spiritual component from cannabis plant, which will not cause hallucinations GW firmly believes that the drug can reduce the spasm of some serious children's epilepsy The FDA of the United States has successively granted the company the qualification of epidieolex orphan drug and Dravet orphan drug for the treatment of Lennox Gastaut syndrome (LGS) in children Conclusion: the pharmaceutical industry is closely related to people's health In order to bring more good drugs and reassuring drugs to patients, many pharmaceutical companies are actively doing experiments and research and development The two pharmaceutical companies on the list are not only for their affirmation in the pharmaceutical field, but also for their future development I believe that inspired by more and more mature medical technology, the two pharmaceutical companies can make more contributions to the healthy development of human beings.